Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total glucosides of paeony plus standard therapy in mild active systemic lupus erythematosus
ChiCTR2500104846Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Wenzhou Medical University
- Start
- Jun 2025
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of total glucosides of paeony in systemic lupus erythematosus (SLE) (2 arms), sponsored by The First Affiliated Hospital of Wenzhou Medical University. Primary endpoints: Low disease activity status (LLDAS) at week 24, Sustained LLDAS for more than 3 months and 2 more. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
total glucosides of paeony
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2500104846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104846.